Iovance Biotherapeutics is trading at $8.61, up 4.03% on September 2, 2026, alongside a 2.75% gain in the XBI biotech ETF amid positive patent news and continued industry momentum.
- No new company-specific announcement or direct catalyst was identified.
- Recent second-quarter results remain a favorable backdrop, with record Amtagvi-driven revenue; those results were reported August 6, not September 2.